Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
2.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

3.

Antinuclear Antibodies and Lupus: Label Versus Meaning.

Daikh DI.

Arthritis Care Res (Hoboken). 2019 Nov;71(11):1401-1403. doi: 10.1002/acr.23913. No abstract available.

PMID:
31058455
4.

ACR Presidential Address: Building on the Strengths of Our Unique Specialty.

Daikh DI.

Arthritis Rheumatol. 2019 May;71(5):664-669. doi: 10.1002/art.40846. No abstract available.

PMID:
30698363
5.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

6.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
7.

How Should We Consider Lupus Without Antinuclear Antibodies?

Daikh DI, Aringer M.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):853-854. doi: 10.1002/acr.23714. No abstract available.

PMID:
30035362
8.

Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients.

Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, Dörner T, Johnson SR, Aringer M; ; on behalf of the SLE Classification Criteria Steering Committee.

Lupus. 2018 Aug;27(9):1431-1436. doi: 10.1177/0961203318776093. Epub 2018 May 17.

PMID:
29771193
9.

Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13.

10.

Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S.

Ann Rheum Dis. 2018 Jun;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565. Epub 2018 Mar 13.

PMID:
29525777
11.

Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus.

Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T; SLE classification criteria steering committee and the international SLE expert panel of the initiative.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1488-1494. doi: 10.1002/acr.23503. Epub 2018 Sep 11.

12.

Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):571-581. doi: 10.1002/acr.23317. Epub 2018 Feb 22. Review.

13.

Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data.

Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, Johnson SR, Daikh D, Dörner T, Aringer M, Bertsias G; Systemic Lupus Erythematosus Classification Criteria Steering Committee.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):428-438. doi: 10.1002/acr.23292. Epub 2018 Jan 30.

14.

How Do We Classify "Incomplete Lupus?"

Daikh DI, Costenbader KH.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1777-1779. doi: 10.1002/acr.23196. No abstract available.

15.

Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate.

Schmajuk G, Tonner C, Miao Y, Yazdany J, Gannon J, Boscardin WJ, Daikh DI, Steinman MA.

PLoS One. 2016 Dec 15;11(12):e0168369. doi: 10.1371/journal.pone.0168369. eCollection 2016.

16.

Serum biomarkers of inflammation and muscle strength among women with systemic lupus erythematosus.

Andrews JS, Trupin L, Hough CL, Daikh DI, Yelin EH, Katz PP.

Cytokine. 2017 Feb;90:109-112. doi: 10.1016/j.cyto.2016.11.003. Epub 2016 Nov 16.

17.

Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic.

Bays A, Wahl E, Daikh DI, Yazdany J, Schmajuk G.

BMC Health Serv Res. 2016 Aug 15;16(a):384. doi: 10.1186/s12913-016-1633-x.

18.

Advances in managing ankylosing spondylitis.

Daikh DI, Chen PP.

F1000Prime Rep. 2014 Sep 4;6:78. doi: 10.12703/P6-78. eCollection 2014. Review.

19.

Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA.

Arthritis Care Res (Hoboken). 2014 Aug;66(8):1159-66. doi: 10.1002/acr.22294.

20.

Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.

Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, Barton J, Carlson A, Margaretten M, Zell J, Gensler LS, Kelly V, Saag K, King C; American College of Rheumatology Core Membership Group.

Arthritis Care Res (Hoboken). 2013 Mar;65(3):329-39. doi: 10.1002/acr.21930.

21.

A randomized trial of stress management for the prevention of new brain lesions in MS.

Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D.

Neurology. 2012 Jul 31;79(5):412-9. doi: 10.1212/WNL.0b013e3182616ff9. Epub 2012 Jul 11.

22.

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664. No abstract available.

23.

Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.

Daikh DI, St Clair EW.

Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659. No abstract available.

24.

Rheumatic manifestations of cancer.

Ashouri JF, Daikh DI.

Rheum Dis Clin North Am. 2011 Nov;37(4):489-505. doi: 10.1016/j.rdc.2011.09.001. Review.

PMID:
22075194
25.

Resolution of recurrent fusarium arthritis after prolonged antifungal therapy.

Charles JF, Eberle C, Daikh DI, Rooney T.

J Clin Rheumatol. 2011 Jan;17(1):44-5. doi: 10.1097/RHU.0b013e318205669d. No abstract available.

PMID:
21169847
26.

Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells.

Scalapino KJ, Daikh DI.

PLoS One. 2009 Jun 24;4(6):e6031. doi: 10.1371/journal.pone.0006031.

27.

B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.

Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A.

J Exp Med. 2008 Nov 24;205(12):2755-61. doi: 10.1084/jem.20081204. Epub 2008 Nov 10.

28.

CTLA-4: a key regulatory point in the control of autoimmune disease.

Scalapino KJ, Daikh DI.

Immunol Rev. 2008 Jun;223:143-55. doi: 10.1111/j.1600-065X.2008.00639.x. Review.

PMID:
18613834
29.

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI.

Arthritis Rheum. 2008 May;58(5):1433-44. doi: 10.1002/art.23428.

30.

Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?

Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE Jr.

Am J Respir Crit Care Med. 2007 Oct 1;176(7):691-7. Epub 2007 Jun 7.

31.

Novel model of antigen-specific induction of bile duct injury.

Buxbaum J, Qian P, Khuu C, Shneider BL, Daikh DI, Gershwin ME, Allen PM, Peters MG.

Gastroenterology. 2006 Dec;131(6):1899-906. Epub 2006 Oct 14.

32.
33.

Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases.

Daikh DI, Gillis J, Wofsy D.

Arthritis Rheum. 2006 Apr 15;55(2):322-4. No abstract available.

34.

The Vioxx debacle revisited.

Daikh DI.

Am J Med. 2005 Sep;118(9):1057. No abstract available.

PMID:
16164908
35.

Block and tackle: CTLA4Ig takes on lupus.

Davidson A, Diamond B, Wofsy D, Daikh D.

Lupus. 2005;14(3):197-203. Review.

PMID:
15807196
36.

Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.

Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, Yen TS, Daikh DI.

Arthritis Rheum. 2004 May;50(5):1539-48.

37.

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.

Cunnane G, Warnock M, Fye KH, Daikh DI.

Arthritis Rheum. 2002 Aug;47(4):445-9. No abstract available.

38.

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J.

BMJ. 2002 Jun 22;324(7352):1488-92.

39.

Treatment of autoimmune diseases by inhibition of T-cell costimulation.

Wofsy D, Daikh DI.

Mod Rheumatol. 2002 Mar;12(1):1-4. doi: 10.3109/s101650200000.

PMID:
24383824
40.

Treatment of autoimmunity by inhibition of T cell costimulation.

Daikh DI, Wofsy D.

Adv Exp Med Biol. 2001;490:113-7. Review. No abstract available.

PMID:
11505969
41.
42.

An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity.

Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A.

Cell. 2000 Dec 22;103(7):1059-70.

43.

Effects of anti-B7 monoclonal antibodies on humoral immune responses.

Daikh DI, Wofsy D.

J Autoimmun. 1999 Mar;12(2):101-8.

PMID:
10047430
44.

Opportunities for future biological therapy in SLE.

Wofsy D, Daikh DI.

Baillieres Clin Rheumatol. 1998 Aug;12(3):529-41. Review.

PMID:
9890111
45.

On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases.

Daikh DI, Wofsy D.

Transplant Proc. 1998 Dec;30(8):4027-8. Review. No abstract available.

PMID:
9865285
46.

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D.

J Immunol. 1997 Oct 1;159(7):3104-8.

PMID:
9317105
47.

The CD28-B7 costimulatory pathway and its role in autoimmune disease.

Daikh D, Wofsy D, Imboden JB.

J Leukoc Biol. 1997 Aug;62(2):156-62. Review.

PMID:
9261329
48.

Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years.

Neuwelt CM, Daikh DI, Linfoot JA, Pfister DA, Young RG, Webb RL, London SS, Asherson RA.

Arthritis Rheum. 1997 Aug;40(8):1534-9.

PMID:
9259436
49.

Structure and expression of the human motilin gene.

Daikh DI, Douglass JO, Adelman JP.

DNA. 1989 Oct;8(8):615-21.

PMID:
2574660
50.

In situ hybridization detection of marked differences in pre-proopiomelanocortin messenger ribonucleic acid content of individual corticotropes and melanotropes.

Hatfield JM, Daikh DI, Adelman JP, Douglass J, Bond CT, Allen RG.

Endocrinology. 1989 Mar;124(3):1359-64.

PMID:
2537180

Supplemental Content

Support Center